Everybody jump, Vir Biotechnology stock jumps 22% pre-market
Landon Capital News
Vir Biotechnology, Inc. (NASDAQ: VIR) shares jumped 22% Monday after the company announced that its Phase 3 ECLIPSE 1 trial evaluating elebsiran and tobevibart in adults with chronic hepatitis delta met all primary and key secondary endpoints.
The trial’s primary endpoint was achieved, with 44% of patients receiving the drug combination recording undetectable virus levels alongside normalized alanine aminotransferase (ALT) levels at Week 48, compared with 0% in the delayed-treatment group at Week 12.
The trial also met its key secondary endpoint, with 79% of patients receiving the combination achieving undetectable virus levels at Week 48, versus 0% in the delayed-treatment group.
ECLIPSE 1 enrolled 124 patients, randomized in a 2:1 ratio to receive monthly subcutaneous injections of elebsiran and tobevibart or delayed treatment. The study included a geographically diverse population across multiple countries, including patients with advanced liver disease.
About Landon Capital
Landon Capital Inc. is a media company that wholly owns subsidiaries Landon Capital Management LLC and Landon Capital News. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.
Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Landon Capital received no direct compensation related to this release. This release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Actual results may differ materially from those stated or implied in.
